(EWTX) – Company Press Releases
-
Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies
-
Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)
-
Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session
-
Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024
-
Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024
-
Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference
-
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
-
Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne)
-
Edgewise Therapeutics Announces Pricing of $240 Million Underwritten Offering of Common Stock
-
Edgewise Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference
-
Edgewise Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024
-
Edgewise Therapeutics Launches First of Its Kind Educational Website Dedicated to the Becker Muscular Dystrophy Community
-
Edgewise Receives Orphan Drug and Rare Pediatric Disease Designations for Its Muscular Dystrophy Program from FDA
-
Edgewise Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
-
Edgewise Therapeutics to Present at Upcoming Investor Conferences
-
Edgewise to Present Data on EDG-7500 at the American Heart Association’s Scientific Sessions 2023
-
Edgewise Therapeutics Announces Expansion of their EDG-5506 Clinical Program in Duchenne Muscular Dystrophy (Duchenne)
-
Edgewise Therapeutics to Present on EDG-5506 for Becker Muscular Dystrophy at the 28th International Annual Congress of the World Muscle Society
-
Edgewise Therapeutics Announces Initiation of GRAND CANYON, a Global Pivotal Study of EDG-5506 in Becker Muscular Dystrophy (Becker)
-
Edgewise Therapeutics Begins Dosing First-in-Human Phase 1 Trial of EDG-7500, its Lead Clinical Candidate for Hypertrophic Cardiomyopathy (HCM) and Other Serious Diseases of Cardiac Diastolic Dysfunct
-
Edgewise Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
-
Edgewise Therapeutics Announces Positive 12-Month Topline Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)
-
Edgewise Therapeutics to Present at the Goldman Sachs Global Healthcare Conference
-
Edgewise Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
-
Edgewise Therapeutics to Present at Upcoming Investor Conferences
-
Edgewise Therapeutics Announces Journal of Clinical Investigation Publication of Key Preclinical Data Linking Modulation of Fast Skeletal Muscle Contraction to Protection of Skeletal Muscle in Models
-
Edgewise Therapeutics to Present at the Stifel 2023 CNS Days on March 28, 2023
-
Edgewise Therapeutics to Present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 2023 Annual MDA Clinical and Scientific Conference
-
Edgewise Therapeutics Appoints Industry Veteran Jonathan C. Fox, M.D., Ph.D., FACC to its Board of Directors
-
Edgewise Therapeutics to Present at the Cowen 43rd Annual Health Care Conference on March 8, 2023
-
Edgewise Therapeutics Announces Upcoming Presentation at the American College of Cardiology's 72nd Annual Scientific Session Together with World Congress of Cardiology
-
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
-
Edgewise Therapeutics to Present at the SVB Securities Global Biopharma Conference on February 14, 2023
-
Edgewise Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023
-
Edgewise Therapeutics to Showcase Novel Cardiac Program at Virtual Investor Event on Tuesday, January 3, 2023
-
Edgewise Therapeutics Appoints Marc Semigran, M.D., As Chief Development Officer
-
Edgewise Therapeutics to Present at Upcoming Investor Conferences
-
Edgewise Therapeutics Reports Third Quarter 2022 Financial Results
-
Edgewise Therapeutics Announces Initiation of LYNX Phase 2 Clinical Trial of EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (DMD)
-
Edgewise Therapeutics Announces Positive 6-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)
-
Edgewise Therapeutics to Present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 27th International Hybrid Annual Congress of the World Muscle Society
-
Edgewise Therapeutics Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Edgewise Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
-
Edgewise Therapeutics Announces Proposed Offering of Common Stock
-
Edgewise Therapeutics Announces Positive 4-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)
-
Edgewise Therapeutics Announces FDA Authorization for Phase 2 Clinical Trial of EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (DMD)
-
Edgewise Therapeutics Reports Second Quarter 2022 Financial Results
-
Edgewise Therapeutics to Present at the Wedbush PacGrow Healthcare Conference on August 9
-
Edgewise Therapeutics Now Enrolling CANYON Phase 2 Clinical Trial of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD)
-
Edgewise Therapeutics Announces Positive 2-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)
Back to EWTX Stock Lookup
